Search Results - "Fram, Robert"

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML by Sekeres, Mikkael A., Watts, Justin, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua F., Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., Adès, Lionel

Get full text

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants by Hanley, Michael J., Zhang, Steven, Griffin, Robert, Zhu, Sean Xiaochun, Fram, Robert J., Lin, Jianchang, Venkatakrishnan, Karthik, Gupta, Neeraj

“…Mobocertinib (TAK-788) is a first-in-class oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that received accelerated approval for the…”
Get full text

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes by Zeidner, Joshua F, Mazerolle, Flora, Norton, Jonathan, Regnault, Antoine, Kristo, Fjoralba, Romero, Heather, Fram, Robert J, Faller, Douglas V, Dalal, Mehul, Ades, Lionel, Sekeres, Mikkael A

Get full text

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations by Yoh, Kiyotaka, Azuma, Koichi, Hayashi, Hidetoshi, Nishio, Makoto, Chikamori, Kenichi, Ichihara, Eiki, Watanabe, Yasutaka, Asato, Takayuki, Kitagawa, Tadayuki, Fram, Robert J., Ohe, Yuichiro

“…Background Mobocertinib is a novel, synthetic, orally administered tyrosine kinase inhibitor that inhibits many activated forms of epidermal growth factor…”
Get full text

Mobocertinib: Mechanism of action, clinical, and translational science by Hanley, Michael J., Camidge, D. Ross, Fram, Robert J., Gupta, Neeraj

“…Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent ~6%–12% of all EGFR‐mutated non‐small cell lung cancer (NSCLC) cases…”
Get full text

XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer by Yurkovetskiy, Alexander V., Fram, Robert J.

“…An overview of XMT-1001 is provided in the context of other topoisomerase I inhibitors conjugated to polymers or encapsulated in liposomes. XMT-1001 is a novel…”
Get full text

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML by Adès, Lionel, Girshova, Larisa, Doronin, Vadim A., Díez-Campelo, María, Valcárcel, David, Kambhampati, Suman, Viniou, Nora-Athina, Woszczyk, Dariusz, De Paz Arias, Raquel, Symeonidis, Argiris, Anagnostopoulos, Achilles, Munhoz, Eduardo Ciliao, Platzbecker, Uwe, Santini, Valeria, Fram, Robert J., Yuan, Ying, Friedlander, Sharon, Faller, Douglas V., Sekeres, Mikkael A.

“…PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monotherapy (n = 227) in patients with newly diagnosed…”
Get full text

Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States by Bell, Jill A., Galaznik, Aaron, Farrelly, Eileen, Blazer, Marlo, Murty, Sharanya, Ogbonnaya, Augustina, Eaddy, Michael, Fram, Robert J., Faller, Douglas V., Kota, Vamsi

“…[Display omitted] •Healthcare utilization in elderly acute myeloid leukemia patients is substantial.•92% of our population had ≥1 hospital admission over the…”
Get full text

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML by Sekeres, Mikkael A., Watts, Justin, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua F., Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., Adès, Lionel

Get full text

A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent by Bell, Jill A., Galaznik, Aaron, Farrelly, Eileen, Blazer, Marlo, Murty, Sharanya, Ogbonnaya, Augustina, Eaddy, Michael, Fram, Robert J., Faller, Douglas V., Kota, Vamsi K.

“…•More elderly acute myeloid leukemia patients used more intensive induction therapy.•Patients with less intensive induction therapy were older with more…”
Get full text

Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia by Bell, Jill A., Galaznik, Aaron, Huelin, Rachel, Stokes, Michael, Guo, Yelan, Fram, Robert J., Faller, Douglas V.

“…High-dose chemotherapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) can produce long-term remission in patients with higher-risk…”
Get full text

Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care by Bell, Jill A., Galaznik, Aaron, Blazer, Marlo, Farrelly, Eileen, Ogbonnaya, Augustina, Raju, Aditya, Eaddy, Michael, Fram, Robert J., Faller, Douglas V.

“…Most higher-risk myelodysplastic syndrome (HR-MDS) patients will become transfusion-dependent, leading to potential complications, including infections or…”
Get full text

Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30 by Regnault, Antoine, Pompilus, Farrah, Ciesluk, Anna, Mazerolle, Flora, Bejar, Rafael, Fram, Robert J., Faller, Douglas V., Marquis, Patrick, Bell, Jill A.

“…Purpose Physical functioning and fatigue are key patient concerns in myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid…”
Get full text

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review by Bell, Jill A., Galaznik, Aaron, Huelin, Rachel, Stokes, Michael, Guo, Yelan, Fram, Robert J., Faller, Douglas V.

“…Acute myeloid leukemia (AML) is the second most common leukemia among adults. Although the median age at diagnosis is 67 years, with approximately one third of…”
Get full text

Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts by WALSH, Mark D, HANNA, Suzan K, SEN, Jeremy, RAWAL, Sumit, CABRAL, Carolina B, YURKOVETSKIY, Alex V, FRAM, Robert J, LOWINGER, Timothy B, ZAMBONI, William C

“…To evaluate the pharmacokinetics and tissue disposition of macromolecular camptothecin (CPT) drug conjugate, XMT-1001, and irinotecan (CPT-11) in mice bearing…”
Get full text

A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia by Bell, Jill A., Galaznik, Aaron, Pompilus, Farrah, Strzok, Sara, Bejar, Rafael, Scipione, Fatima, Fram, Robert J., Faller, Douglas V., Cano, Stefan, Marquis, Patrick

“…Background Novel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial…”
Get full text

Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States by Bell, Jill A., Galaznik, Aaron, Blazer, Marlo, Shih, Huai-Che, Farrelly, Eileen, Ogbonnaya, Augustina, Eaddy, Michael, Fram, Robert J., Faller, Douglas V.

“…Background and Objective Significant clinical burden is associated with higher-risk myelodysplastic syndromes (HR-MDS); however, the economic burden has not…”
Get full text

A clinically relevant SCID-hu in vivo model of human multiple myeloma by Tassone, Pierfrancesco, Neri, Paola, Carrasco, Daniel R., Burger, Renate, Goldmacher, Victor S., Fram, Robert, Munshi, Vidit, Shammas, Masood A., Catley, Laurence, Jacob, Gary S., Venuta, Salvatore, Anderson, Kenneth C., Munshi, Nikhil C.

“…We developed a novel in vivo multiple myeloma (MM) model by engrafting the interleukin 6 (IL-6)-dependent human MM cell line INA-6 into severe combined…”
Get full text

A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors by EBBINGHAUS, Scot, RUBIN, Eric, HERSH, Evan, CRANMER, Lee D, BONATE, Peter L, FRAM, Robert J, JEKUNEN, Antti, WEITMAN, Steve, HAMMOND, Lisa A

“…Purpose: To determine the maximum tolerated dose, dose-limiting toxicity, and pharmacokinetics of the dolastatin-15 analogue, tasidotin (ILX651), when…”
Get full text

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors by CUNNINGHAM, Casey, APPLENIAN, Leonard J, WEITMAN, Steve, HAMMOND, Lisa A, EDER, Joseph P, KIRVAN-VISOVATTI, Miora, RYAN, David P, REGAN, Eileen, VUKELJA, Svetislava, BONATE, Peter L, RUVUNA, Francis, FRAM, Robert J, JEKUNEN, Antti

“…Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of tasidotin (ILX651), a dolastatin-15 analogue,…”
Get full text